Interleukin‐33/ST2 Axis Promotes Epithelial Cell Transformation and Breast Tumorigenesis via Upregulation of COT Activity

Abstract

Cytokines of the interleukin‐1 (IL‐1) family, such as IL‐1α/β and IL‐18, have pleiotropic activities in innate and adaptive immune responses in host defense and diseases. Insight into their biological functions helped develop novel therapeutic approaches to treat human inflammatory diseases. IL‐33 is an important member of the IL‐1 family of cytokines and is a ligand of the ST2 receptor, a member of the IL‐1 receptor family. However, the role of the IL‐33/ST2 axis in tumor growth and metastasis of breast cancer remains unclear. Here, we demonstrate that IL‐33 is a critical tumor promoter during epithelial cell proliferation and tumorigenesis in the breast. IL‐33 dose‐ and time‐dependently increased Cancer Osaka Thyroid (COT) phosphorylation via ST2‐COT interaction in normal epithelial and breast cancer cells. The IL‐33/ST2/COT cascade induced the activation of the MEK‐ERK, JNK‐cJun and STAT3 signaling pathways, followed by increased AP‐1 and stat3 transcriptional activity. When small interfering RNAs of ST2 and COT were introduced into cells, IL‐33‐induced AP‐1 and stat3 activity were significantly decreased, unlike that in the control cells. The inhibition of COT activity resulted in decreased IL‐33‐induced epithelial cell transformation, and knockdown of IL‐33, ST2 and COT in breast cancer cells attenuated tumorigenicity of breast cancer cells. Consistent with these observations, ST2 levels were positively correlated with COT expression in human breast cancer. These findings provide a novel perspective on the role of the IL‐33/ST2/COT signaling pathway in supporting cancer‐associated inflammation in the tumor microenvironment. Therapeutic approaches that target this pathway may, therefore, effectively inhibit carcinogenesis in the breast.